Literature DB >> 11600430

Activation of G551D CFTR channel with MPB-91: regulation by ATPase activity and phosphorylation.

R Dérand1, L Bulteau-Pignoux, Y Mettey, O Zegarra-Moran, L D Howell, C Randak, L J Galietta, J A Cohn, C Norez, L Romio, J M Vierfond, M Joffre, F Becq.   

Abstract

We have designed and synthesized benzo[c]quinolizinium derivatives and evaluated their effects on the activity of G551D cystic fibrosis transmembrane conductance regulator (CFTR) expressed in Chinese hamster ovary and Fisher rat thyroid cells. We demonstrated, using iodide efflux, whole cell patch clamp, and short-circuit recordings, that 5-butyl-6-hydroxy-10-chlorobenzo[c]quinolizinium chloride (MPB-91) restored the activity of G551D CFTR (EC(50) = 85 microM) and activated CFTR in Calu-3 cells (EC(50) = 47 microM). MPB-91 has no effect on the ATPase activity of wild-type and G551D NBD1/R/GST fusion proteins or on the ATPase, GTPase, and adenylate kinase activities of purified NBD2. The activation of CFTR by MPB-91 is independent of phosphorylation because 1) kinase inhibitors have no effect and 2) the compound still activated CFTR having 10 mutated protein kinase A sites (10SA-CFTR). The new pharmacological agent MPB-91 may be an important candidate drug to ameliorate the ion transport defect associated with CF and to point out a new pathway to modulate CFTR activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11600430     DOI: 10.1152/ajpcell.2001.281.5.C1657

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  15 in total

1.  Designer pharmacotherapy for the treatment of cystic fibrosis: commentary on Zegarra-Moran et al.

Authors:  M A Gray
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

2.  Enhancing the Potency of F508del Correction: A Multi-Layer Combinational Approach to Drug Discovery for Cystic Fibrosis.

Authors:  Emily F Kirby; Ashley S Heard; X Robert Wang
Journal:  J Pharmacol Clin Toxicol       Date:  2013-08-28

3.  C terminus of nucleotide binding domain 1 contains critical features for cystic fibrosis transmembrane conductance regulator trafficking and activation.

Authors:  Arnaud Billet; Patricia Melin; Mathilde Jollivet; Jean-Paul Mornon; Isabelle Callebaut; Frédéric Becq
Journal:  J Biol Chem       Date:  2010-04-30       Impact factor: 5.157

4.  Curcumin and genistein additively potentiate G551D-CFTR.

Authors:  Ying-Chun Yu; Haruna Miki; Yumi Nakamura; Akiko Hanyuda; Yohei Matsuzaki; Yoichiro Abe; Masato Yasui; Kazuhiko Tanaka; Tzyh-Chang Hwang; Silvia G Bompadre; Yoshiro Sohma
Journal:  J Cyst Fibros       Date:  2011-03-26       Impact factor: 5.482

5.  A potentiator induces conformational changes on the recombinant CFTR nucleotide binding domains in solution.

Authors:  Elena Galfrè; Lauretta Galeno; Oscar Moran
Journal:  Cell Mol Life Sci       Date:  2012-07-03       Impact factor: 9.261

6.  Direct effects of 9-anthracene compounds on cystic fibrosis transmembrane conductance regulator gating.

Authors:  Tomohiko Ai; Silvia G Bompadre; Yoshiro Sohma; Xiaohui Wang; Min Li; Tzyh-Chang Hwang
Journal:  Pflugers Arch       Date:  2004-10       Impact factor: 3.657

7.  Comparative pharmacology of the activity of wild-type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative NS004.

Authors:  R Dérand; L Bulteau-Pignoux; F Becq
Journal:  J Membr Biol       Date:  2003-07-15       Impact factor: 1.843

Review 8.  Curcumin and genistein: the combined effects on disease-associated CFTR mutants and their clinical implications.

Authors:  Yoshiro Sohma; Ying-Chun Yu; Tzyh-Chang Hwang
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

9.  General anesthetic octanol and related compounds activate wild-type and delF508 cystic fibrosis chloride channels.

Authors:  Brice Marcet; Frédéric Becq; Caroline Norez; Patrick Delmas; Bernard Verrier
Journal:  Br J Pharmacol       Date:  2004-02-16       Impact factor: 8.739

Review 10.  Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors.

Authors:  Luis J V Galietta
Journal:  Paediatr Drugs       Date:  2013-10       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.